DELAWARE – March 29, 2021 – Global law firm Greenberg Traurig, LLP represented NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, in connection with its initial public offering (IPO) on the Korea Exchange (KOSDAQ).
As part of the IPO, the company sold 3,133,334 shares of common stock, equivalent to 15,666,670 Korea Depository Receipts (KDRs), priced at KRW 37,500 per share. The aggregate gross proceeds to NeoImmuneTech, before deducting underwriting discounts and commissions and other offering expenses, were KRW 117.5 billion ($103.4 million). NeoImmuneTech trades under the KOSDAQ code number “950220.”
Hana Financial Investment and Mirae Asset Daewoo acted as joint book-running managers for the offering and Bae, Kim & Lee LLC were lead and Korean legal counsel for it. The Greenberg Traurig team, led by Delaware office Shareholder Justin Mann, included Vice Chair of Greenberg Traurig Richard A. Edlin, and Shareholders Chang Joo Kim, and Diane Ibrahim as well as Shareholders Joseph Agostino, Ian Herbert, Leanne M. Reagan, Jason T. Simon, Robert Simon; Of Counsel Eleanor A. Kolton; Project Attorney Mary F. Voce; Associates Necky Deneus, Christopher E. Gottfried, Joshua M. Herman, Kathleen M. Kline, and Glenn J. Thompson.